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Muramyl dipeptideThe NOD-like receptor NLRP1 (NLR family, pyrin domain containing 1) senses the presence of the
bacterial cell wall component L-muramyl dipeptide (MDP) inside the cell. We determined the crystal
structure of the LRR domain of human NLRP1 in the absence of MDP to a resolution of 1.65 Å. The
fold of the structure can be assigned to the ribonuclease inhibitor-like class of LRR proteins. We
compared our structure with X-ray models of the LRR domains of NLRX1 and NLRC4 and a homology
model of the LRR domain of NOD2. We conclude that the MDP binding site of NLRP1 is not located in
the LRR domain.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction possess a pyrine domain (PYD) as effector binding domain whereasIn higher eukaryotes the innate immune system constitutes the
ﬁrst line of defence against invading pathogens like bacteria,
viruses and fungi [1]. The two principal families of pathogen detec-
tors are the Toll-like receptors (TLRs) and the NOD-like receptors
(NLRs). The TLRs embedded in the plasma membrane recognize
extracellular danger signals in the form of so-called pathogen asso-
ciated molecular patterns (PAMPs) [2], whereas the NLRs strictly
act as intracellular PAMP sensors [3]. NLRs contain an N-terminal
effector binding domain, a nucleotide-binding domain (NBD), and
a C-terminal regulatory domain formed by a varying number of
leucine-rich repeats (LRR) (Fig. 1) [4]. According to their effector
domains, NLRs can be subdivided into four groups, of which the
NLRPs and the NLRCs constitute the major sub-groups. All NLRPsNLRCs contain a caspase recruitment domain (CARD) [5]. When
activated by a speciﬁc PAMP, NLRs are supposed to form a large
signaling complex termed inﬂammasome [6]. The inﬂammasome
recruits and activates proinﬂammatory caspases (cysteine-depen-
dent aspartate-directed proteases), which start a signaling cascade
ultimately leading to inﬂammatory responses [7]. For several NLR
family members activating PAMPs have been identiﬁed, e.g.
L-muramyl dipeptide (MDP) for NLRP1 (in older literature referred
to as NALP1) [8] and NOD2 [9], diamino pimelic acid (DAP) for
NOD1 [10], and as diverse agents as uric acid crystals, maitotoxin,
asbestos, and silica for NLRP3 [11–13]. A direct activation by a
putative ligand has been shown in vitro for NLRP1 [8], NOD1
[14], NOD2 [15] and NLRX1 [16]. By analogy to the TLRs the LRR
domain of NLRs has been postulated as the PAMP binding region
[5,17], which has been conﬁrmed for NOD1 [14] and NLRX1 [16].
Structural information at the atomic level about NLR family
members is conﬁned to crystal or NMR structures of the PYDs of
several NLRPs [18–23], the CARDs of NLRP1 and NOD1 [23,24],
the RNA-binding domain of NLRX1 [16], and the crystal structure
of autoinhibited PYD-deleted NLRC4 (IPAF) in the absence of acti-
vating ligand [25].
NLRs are intracellular sensors for invading pathogens and are
part of the innate immune system. The mechanism of PAMP sens-
ing and activation of the NLRs is of high interest for a better under-
standing of the processes that occur during host immune response.
Fig. 1. Domain structure of selected NLRs. The different domains are: PYD – pyrin domain; NOD – nucleotide binding and oligomerization domain; LRR – leucine-rich repeat;
FIIND – function to ﬁnd; CARD – caspase recruitment domain; MT – mitochondrial targeting; THB – three-helix bundle. The total number of amino acids is given on the right.
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pathogen recognition and to severe autoinﬂammatory diseases like
Crohn’s disease, Muckle–Wells syndrome, and vitiligo [26]. In this
context the mechanism of ligand recognition is one of the most
interesting but least understood parts in the function of NLRs.
We have recombinantly produced the LRR domain of NLRP1
(NLRP1–LRR). We solved the crystal structure of NLRP1–LRR and
compared our structure with existing models of the LRR domains
of NLRX1, NLRC4, and NOD2. Based on our results we propose that
ligand recognition in NLRP1 is not mediated by the LRR domain.
2. Materials and methods
2.1. Protein expression and puriﬁcation
The coding sequence corresponding to residues 791–990 was
ampliﬁed via a PCR-based approach from a of human NLRP1 cDNA
clone (IRATp970F1276D, ImaGenes, Berlin, Germany). The DNA
product was cloned into a modiﬁed pGEX-4T-1 vector carrying a
tobacco etch virus (TEV) protease recognition site. The sequence-
veriﬁed construct was transformed into Escherichia coli BL21(DE3)
cells and protein expression was induced by addition of 0.1 mM
isopropyl-b-D-thiogalactopyranoside (IPTG). Cells were grown over
night at 20 C in TB medium.
Cells were harvested by centrifugation, resuspended in buffer A
(50 mMMES-NaOH, pH 6.5, 500 mM NaCl) containing 1 mM phen-
ylmethylsulfonylﬂuorid (PMSF), and 1% v/v NP-40, and were lysed
by sonication. The GST-fusion protein was captured by glutathione
afﬁnity chromatography and was eluted in buffer B (50 mM MES-
NaOH, pH 6.5, 100 mM NaCl) containing 30 mM reduced glutathi-
one. The eluted fusion protein was added with 50 lg TEV/mg and
the mixture was incubated at 4 C overnight. The protein was
loaded onto a 1 ml HiTrap SP column (GE Healthcare) equilibrated
with buffer B. The outlet of the SP column was connected to a 1 ml
HisTrap column (GE Healthcare) to remove the hexahistidine-
tagged TEV protease. After washing, the bound NLRP1–LRR was
eluted using a linear gradient from 100 to 1000 mM NaCl. The peak
fractions were pooled and concentrated using Amicon Ultraﬁltra-
tion devices with a cutoff of 10 kDa. The concentrated protein
was loaded onto a Superdex 75 16/60 size exclusion column (GE
Healthcare) equilibrated with buffer B. Peak fractions were pooled,
ﬁnally puriﬁed via 1 ml GSTrap column (GE Healthcare) to remove
remaining GST, and then concentrated to 15 mg/ml. Small aliquots
were ﬂash frozen in liquid nitrogen and stored at 80 C until fur-
ther use.
2.2. Crystallization and data collection
Crystals were grown at 20 C by mixing 1.5 ll protein solution
(10 mg/ml) with 1.5 ll reservoir solution employing the vapordiffusion method in hanging drop geometry. The optimized reser-
voir solution contained 100 mM Tris (pH 8.0), 20 mM MgCl2, and
25% w/v polyacrylic acid 5100. Crystals were visible after 6 h and
grew to a ﬁnal size of 150  150  400 lm within 3–4 days. Crys-
tals were cryoprotected by short immersion into reservoir solution
containing 30% v/v glycerol and ﬂash cooled in liquid nitrogen. For
co-crystallization we used NLRP1–LRR at a concentration of 15 mg/
ml (680 lM) andMDP at a concentration of 1 mM. The sameMDP
concentration was used for crystal soaking. MDP was purchased
from Invivogen in lyophilized form. Prior to use, stock solutions
of 20 mM MDP in water were prepared. The functional integrity
of the MDP has been conﬁrmed using microscale thermophoresis
with recombinant human calreticulin as binding partner (data
not shown) [27,28]. Native data were collected to 1.65 Å resolution
at beamline X06SA at the Swiss Light Source (Villigen, Switzerland)
at a wavelength of 1.000 Å.
2.3. Data processing, structure determination and reﬁnement
The data were processed with XDS and scaled using XSCALE
[29]. A homology model of the predicted LRR sequence (residues
791–990) was created using MODELLER [30] with the human ribo-
nuclease inhibitor (PDB ID 1Z7X) [31] as a template. Molecular
replacement was performed with PHASER [32] using the homology
model as search model. Model correction and further building was
carried out with COOT [33] and reﬁnement was performed using
REFMAC [34]. The ﬁnal model contains residues 792–989 and has
been reﬁned to Rwork and Rfree values of 13.45% and 18.25%, respec-
tively. Details of data collection and reﬁnement are available from
Table 1. The structure was deposited in the Protein Data Bank as
entry 4IM6.
3. Results and discussion
3.1. Protein puriﬁcation and structure determination
In order to obtain the LRR domain of NLRP1 in a soluble formwe
cloned and expressed various constructs of different lengths. Only
the construct spanning amino acid residues 791–990 (NLRP1–LRR)
was soluble and could be puriﬁed to homogeneity (see Section 2
for details). Sequence analysis and alignments with related NLRs
and other LRR proteins suggests that the fragment 791–990 com-
prises the complete LRR domain of NLRP1 (not shown). This con-
clusion is supported by the fact that all constructs that contained
additional N- or C-terminal residues proved to be insoluble. We
crystallized NLRP1–LRR under various conditions. Best crystals dis-
played the symmetry of the space group 178 (P6122) with unit cell
dimensions of a = b = 84.69 Å and c = 130.47 Å and contained one
molecule per asymmetric unit. This packing leaves a solvent con-
tent of 58.5%. Using synchrotron radiation a complete data set to
Table 1
Crystallographic data collection and reﬁnement statistics.
Data collection
Space group P6122
a, b, c (Å) 84.69, 84.69, 130.47
Resolution (Å) 29.8–1.65 (1.7–1.65)a
Rmerge (%) 3.9 (37.6)
I/r (I) 51.6 (9.7)
Completeness (%) 99.8 (100)
Redundancy 19.8 (17.8)
Reﬁnement
Resolution (Å) 29.8–1.65
No. reﬂections 33,885
Rwork/Rfree 13.45/18.25
No. atoms
Protein 1543
Water 213
B-factors
Protein 29.6
Water 44.5
R.m.s deviations
Bond lengths (Å) 0.023
Bond angles () 2.27
a Values in parentheses are for the highest resolution shell.
Fig. 2. Overall fold of NLRP1–LRR. Leucine rich repeats 1–6 are colored blue, green,
light green, yellow, orange, and red, respectively. The N-terminal capping helix and
the C-terminal b-strand are shown in gray.
T.F. Reubold et al. / FEBS Letters 588 (2014) 3327–3332 33291.65 Å resolution was collected (Table 1). The structure was solved
by molecular replacement using a search model derived from the
human ribonuclease inhibitor (PDB entry 1Z7X) [31].
3.2. Overall structure
The ﬁnal crystallographic model of the NLRP1–LRR contains
amino acid residues 792–989, 213 water molecules, and one glyc-
erol molecule. Residues 791, 990, and the N-terminal peptide
GAMGGS originating from TEV digestion of the GST fusion protein
were not visible in the electron density. The structure has been
reﬁned to Rwork and Rfree values of 13.45% and 18.25%, respectively,
using all data in the resolution range from 29.8 to 1.65 Å resolution
with no sigma cutoff applied (Table 1).
The NLRP1–LRR domain adopts the typical solenoid fold with
approximate dimensions of 50 Å  30 Å  25 Å. The domain con-
sists of six consecutive LRRs, which are N-terminally capped by
an a-helix (Fig. 2). The capping helix comprises the ﬁrst 15 resi-
dues and is directly followed by the ﬁrst LRR. The concave surface
of the LRR domain is formed by a parallel b-sheet with each LRR
contributing one b-strand. The convex surface is formed by short
a-helices that run antiparallel to the b-strands.
Most LRRs contain the conserved sequence motif 1LxxLxLxxC/
NxL11 where xmay be any amino acid [35]. The amino acid residue
at position nine is a cysteine in so-called type A repeats, whereas it
is an asparagine in type B repeats. The complete LRR type A repeat
and type B repeat consist of 28 and 29 amino acid residues, respec-
tively [36–38]. In NLRP1–LRR the ﬁrst ﬁve of its six repeats form
type A and type B alternately, starting with type B. The sixth repeat
possesses a threonine residue (T961) at position nine and displays
a fold distinct from type A or B (Supplementary Fig. S1).
Based on sequence analyses NLRP1–LRR belongs to the ribonu-
clease inhibitor-like (RI-like) subfamily of LRR proteins. Moreover,
we submitted our structural model to the DALI server [39] to
search for the closest structural homologs within the PDB. As
expected, the closest matches were PDB entries containing models
of human, murine, or porcine ribonuclease inhibitors. Comparing
the three-dimensional structures of NLRP1–LRR and porcine
ribonuclease inhibitor (pRI) 177 out of the 198 Ca atoms of
NLRP1–LRR appear to be structurally equivalent with a mean
(r.m.s.) positional deviation of 1.0 Å (Fig. 3A). The alternating order
of the type A and type B repeats seen in the crystal structurecorroborates this classiﬁcation, being the hallmark of RI-like LRR
proteins [37,38]. In addition to solving the apo structure of
NLRP1–LRR, we aimed for visualizing binding of MDP to NLRP1–
LRR by X-ray crystallography. MDP is supposed to be the activating
ligand for NLRP1 [8]. We analyzed NLRP1–LRR crystals soaked with
MDP and crystals grown from a mixture of NLRP1–LRR and MDP.
However, electron density maps derived from putative co-crystals
obtained by either approach were devoid of density for a ligand. In
their in vitro study, Faustin et al. (2007) employed recombinant
full-length NLRP1 produced in insect cells at a concentration of
8.5 nM and MDP at a concentration of 200 nM (0.1 lg/ml). These
concentrations were sufﬁcient to activate NLRP1, reﬂected in the
formation of functional inﬂammasomes [8]. The concentrations
of MDP and of protein used in our crystallization trials exceeded
the dissociation constant inferred from Faustin et al. [8] by far.
Therefore we would expect potential MDP binding sites of
NLRP1–LRR to be saturated in the crystal. Moreover, the protein
packing in our native NLRP1–LRR crystals leaves spacious channels
and the putative ligand-binding site at the concave side of the
domain (see Section 3.3) is solvent accessible (Supplementary
Fig. S2), allowing MDP in our soaking experiments to freely diffuse
into the crystal and to bind to the protein. In principle, the absence
of ligand density in a crystal structure can be caused by missing
post-translational modiﬁcations on the protein side, suboptimal
Fig. 3. Superposition of NLRP1–LRR with the LRR domains of (A) human ribonuclease inhibitor (PDB ID 1Z7X) [31], (B) NLRX1 (PDB ID 3UN9) [16], (C) NLRC4 (PDB ID 4KXF)
[25], and (D) NOD2 (homology model based on PDB ID 2CA6) [44]. The proteins are displayed as Ca traces. NLRP1–LRR is shown in the coloring scheme of Fig. 2 and its
alignment partners shown in gray.
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Nevertheless, the outcome of the crystallization experiments sup-
ports our view that the LRR domain of NLRP1 does not bind MDP
(see below).
3.3. Structural comparison of NLRP1–LRR with LRR domains
from NLRC4, NLRX1, and a homology model of NOD2–LRR
At present, there are crystal structures of two other LRR
domains of NLR proteins: the structure of CARD-deleted NLRC4
(IPAF) [25] and that of a C-terminal fragment of NLRX1 [16]. Like
NLRP1, NLRX1 and NLRC4 belong to the RI-like subfamily of LRR
proteins [40]. Our DALI search placed the LRR domain of NLRX1
among the best ten matches, whereas NLRC4 was not matched at
all (not shown).
NLRX1 contains seven LRRs that are followed by a three-helix
bundle. Alignment of amino acid residues 707–904 of NLRX1 with
the NLRP1–LRR sequence shows a sequence identity of 27.3% (not
shown). Comparing the three-dimensional structures only 114 out
of the 198 Ca atoms of NLRP1–LRR appear to be structurally equiv-
alent with a mean (r.m.s.) positional deviation of 1.2 Å (Fig. 3B).
The remaining amino acids form loop regions that signiﬁcantly
diverge between the two structures.
NLRC4 contains 14 LRRs, therefore different alignments with
NLRP1–LRR are possible. Interestingly, the best structure-based
alignment lies in a region of NLRC4 where the sequence identity
to NLRP1–LRR is only 9.4%. On the other hand, the highestsequence agreement of 21.8% identity is found superimposing
NLRP1–LRR with amino acid residues 717–918 of NLRC4, which
is a suboptimal alignment on the structural level. In those repeats
the curvature of NLRC4 deviates signiﬁcantly from that of NLRP1–
LRR, which is why the two C-terminal LRRs of NLRP1 were
excluded from the alignment (Fig. 3C). Only 73 out of the 198 Ca
atoms of NLRP1–LRR appear to be structurally equivalent to NLRC4
with a reasonably low r.m.s. deviation of 1.7 Å (Fig. 3C). The larger
structural deviation of NLRC4 appears to reﬂect the larger evolu-
tionary distance of NLRP1 to NLRC4 as compared to NLRX1, as
has been previously noted [41].
NOD2, like NLRP1, is activated upon binding of MDP [15]. A
mutational study on NOD2 identiﬁed residues situated in its LRR
domain that are important for MDP-mediated NF-kB activation
[42]. Based on a homology model of the NOD2–LRR, a subgroup
of these residues is located in the a-helix/turn regions on the con-
vex face of the domain, whereas a second set of loss-of-function
mutations forms a cluster on the concave surface in the C-terminal
half of the LRR [42]. The authors of this study suggested that this
second set of residues is responsible for MDP binding based on a
homology model of NOD2 that is not available to the public [42].
We reasoned that binding of the same PAMP to two different NLRs
has to be mediated by a set of common residues. To compare
NLRP1 and NOD2 on a structural level, we created a homology
model of the LRR domain of NOD2 employing the programMODEL-
LER [43] with the structure of Rna1p (PDB ID 2CA6) [44] as a
template.
Fig. 4. Superposition of NLRP1–LRR with a homology model of NOD2–LRR (based
on PDB ID 2CA6) [44] shown as cartoon representation. NLRP1–LRR is shown in the
coloring scheme of Fig. 2, the NOD2–LRR is displayed in transparent gray. Side
chains of putative MDP-binding residues of NOD2 are displayed in gray, the
equivalent side chains of NLRP1–LRR are shown in yellow for non-conserved
residues and in green for conserved residues, respectively.
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the structure of NLRP1–LRR with the NOD2–LRR homology model
(Fig. 3D). The best structural agreement was achieved with resi-
dues 827–1022 of NOD2 (Supplementary Fig. S3). Sequence-based
alignment also identiﬁed residues 827–1022 of NOD2 as best ﬁt to
NLRP1–LRR with a sequence identity of 29.0%. Only two of the
seven residues identiﬁed by Tanabe et al. [42] as putative MDP-
binding residues in the NOD2–LRR are found in NLRP1–LRR
(Fig. 4 and Supplementary Fig. S3). Therefore, it is unlikely that
those two residues or their counterparts in NLRP1 mediate MDP
binding to the LRR domains. To identify a potential alternative
binding site, we checked the location of all amino acid residues
that are conserved between NLRP1 and NOD2. Apart from the
highly conserved hydrophobic core there are about 15 solvent
exposed residues, which are randomly distributed both on the con-
vex and the concave side of the LRR domain (not shown). These
residues do not form continuous patches, as one would expect
for ligand binding. Therefore, the presence of a conserved MDP
binding site elsewhere in the LRR domain seems unlikely.
Although it was previously thought that NLRP1–LRR is respon-
sible for MDP binding, it is well possible that ligand binding in
NLRP1 is mediated by a domain different from the LRR. A similar
scenario has been shown for NOD2 and NAIP. In NOD2 the NBD
was necessary and sufﬁcient for MDP binding [15]. In murine NAIP
ligand recognition is mediated by an element located within a heli-
cal domain associated with the NBD [45]. These ﬁndings together
with the outcome of our structural comparison argue against the
presence of a PAMP binding site on the NLRP1–LRR.
4. Conclusion
In this work we have determined the crystal structure of the
LRR domain of human NLRP1 to 1.65 Å resolution. From our
detailed structural analysis we conclude that, contradicting the
current view, MDP does not bind to the LRR domain of NLRP1.
The failure of MDP to co-crystallize with NLRP1–LRR supports this
conclusion.
If the LRR domain of NLRP1 does not act as a PAMP sensor, how
then can the activation of full-length NLRP1 by MDP be explained?
It has been shown, that MDP is able to activate full-length NLRP1
in vitro and in vivo [8,46,47]. For the activation of NLRs the autoin-
hibition by the C-terminal domain has to be relieved to enable the
NBD to self-assemble into the active signaling complex. It is gener-
ally believed that this is achieved by PAMP binding to the LRR
domains of NLRs [4,5,17]. In the crystal structure of NLRC4 the
LRR domain makes extensive contacts to the NBD [25]. It is con-
ceivable that binding of bacterial ﬂagellin to the LRR domain ofNLRC4, similar to that of TLR5 [48], disrupts the autoinhibitory
conformation. In the case of the NLR-related protein Apaf-1
(apoptotic protease activating factor 1) the intramolecular inhibi-
tory interaction is disrupted by binding of cytochrome c to the C-
terminal WD40-propellers leading to release of the NBD [49,50].
However, the apparent absence of an MDP binding site on their
LRR domains suggests an alternative mode of action at least for
NLRP1 and NOD2. In this scenario, MDP binding to the NBD results
in the disruption of the inhibitory interface, which then enables the
protein to assemble into the inﬂammasome. This suggests that
PAMP sensing by the LRR domain is not a general feature of NLRs.
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